Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 5, 2025Neuro-OncologyOpen Access

P14.05.b Car T-Cell Therapy Does Not Lead to Medium-Term Neurocognitive Deterioration in Patients With Central Nervous System Lymphomas. A Loc Network Study

View Full Paper
Ask AI
Bookmark
Share

Authors

CHCaroline HouillierSMSirine MersaliRCRémy Chapelle

Discussion

Loading...

Member takes

Overview

Observational analysis shows no medium-term cognitive deterioration in patients with CNS lymphomas, highlighting the safety of CAR T-cell therapy.

Key Points

  • No significant cognitive worsening occurs in patients with CNS lymphomas after CAR T-cell therapy, indicating a positive outcome.
  • At 12 months post-treatment, MoCA scores improved significantly from 23.5 to 26, revealing enhanced cognitive functioning.
  • Data were collected from patients in the French LOC network database, analyzing neurocognitive effects after CAR T-cell treatment.
  • Findings suggest that even patients with severe acute neurotoxicity maintain cognitive stability, necessitating further validation in larger studies.

Cite This Study

Houillier et al. (2025) studied this question.

synapsesocial.com/papers/68e24e6bd6d66a53c2473b5chttps://doi.org/10.1093/neuonc/noaf193.466
View Full Paper
Ask AI
Bookmark
Share